Skip to content

Giovanni Martinotti

University of Chieti-Pescara, University of Hertfordshire

77 papers in the library · 1,635 citations · publishing 2003-2026

Papers

Sort Most recent Most cited

The Loss of Spatiality and Temporality in Twilight Consciousness: The Emergence of Exogenous Psychosis Induced by Novel Psychoactive Substances.

Psychopathology 2024 Valerio Ricci, Giuseppe Maina, Giovanni Martinotti 8 citations

The state of twilight consciousness is marked by a focused narrowing of awareness, maintaining vigilance and attention while simultaneously experiencing perceptual shifts in the surrounding environment. It is crucial to recognize that this twilight state represents not just a contraction but also an expansion of conscious experience. Substances of abuse, particularly new psychoactive...

LSD-induced changes in the functional connectivity of distinct thalamic nuclei.

Neuroimage December 1, 2023 Stefano Delli Pizzi, Piero Chiacchiaretta, Carlo Sestieri et al. 27 citations

The role of the thalamus in mediating the effects of lysergic acid diethylamide (LSD) was recently proposed in a model of communication and corroborated by imaging studies. However, a detailed analysis of LSD effects on nuclei-resolved thalamocortical connectivity is still missing. Here, in a group of healthy volunteers, we evaluated whether LSD intake alters the thalamocortical coupling in a...

Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel

Annals of General Psychiatry November 26, 2023 Giuseppe Maina, Marina Adami, Giuseppe Ascione et al. 56 citations

Abstract Background Treatment-resistant depression (TRD) is defined by the European Medicines Agency as a lack of clinically meaningful improvement after treatment, with at least two different antidepressants. Individual, familiar, and socio-economic burden of TRD is huge. Given the lack of clear guidelines, the large variability of TRD approaches across different countries and the availability...

MDMA-Based Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder (PTSD): A Brief Narrative Overview of Current Evidence

Diseases November 3, 2023 Kainat Riaz, Sejal Suneel, Mohammad Hamza Bin Abdul Malik et al. 16 citations

Post-traumatic stress disorder (PTSD) is a debilitating mental health disorder that causes significant dysfunction in individuals. Currently, there are many approved pharmacotherapy and psychotherapy treatment options for PTSD, but unfortunately, half of the patients do not respond to traditional therapies. In this article, we review clinical trials and research on...

Intranasal esketamine as tool for rapid cycling bipolar disorder: A case report of successful mood stabilization

Psychiatry Research Case Reports October 18, 2023 Giacomo D’andrea, Ornella di Marco, Francesco Maria Semeraro et al. 1 citation

Rapid Cyclic Bipolar Disorder (RCBD) is a debilitating condition that manifests as four or more episodes of depression, mania, or hypomania in a span of one year, with depression being the predominant event. RCBD is prevalent among individuals diagnosed with bipolar disorder and is associated with elevated suicide risk, prolonged disease duration, unfavorable clinical outcomes, and cognitive...

Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment‐resistant depression

Acta Psychiatrica Scandinavica September 8, 2023 Giacomo D’andrea, Mauro Pettorruso, T. Rhee et al. 8 citations

Depressive disorders represent a significant economic and health burden globally. This is particularly evident in treatment-resistant depression (TRD), commonly defined as the absence of a satisfactory response to at least two different antidepressant trials (as defined by the U.S. Food and Drug Administration/FDA and European Medicine Agencies/EMA). The foregoing TRD cases frequently manifest...

Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)

Psychiatry Research July 29, 2023 Mauro Pettorruso, Roberto Guidotti, Giacomo D’andrea et al. 56 citations

Treatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA and FDA, but data about predictors of response are still lacking. Thus, a tool that can predict the individual patients' probability of response to ESK-NS is needed. This study investigates sociodemographic and...

Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group

American Journal of Geriatric Psychiatry July 8, 2023 Giacomo D’andrea, Stefania Chiappini, Roger S McIntyre et al. 36 citations

INTRODUCTION: Treatment-resistant depression (TRD) is a serious and debilitating psychiatric disorder that frequently affects older patients. Esketamine nasal spray (ESK-NS) has recently been approved as a treatment for TRD, with multiple studies establishing its efficacy and tolerability. However, the real-world effectiveness, tolerability, and safety of this treatment in older adults is still...

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study

European Neuropsychopharmacology May 4, 2023 Stefania Chiappini, Giacomo D’andrea, Sergio De Filippis et al. 48 citations

Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety. It is also indicated for the acute short-term treatment of psychiatric emergency due to major depressive disorder (MDD) and for depressive symptoms in adults with MDD with acute suicidal...

Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression

Bipolar Disorders January 13, 2023 Giovanni Martinotti, Bernardo Dell’osso, Giorgio Di Lorenzo et al. 72 citations

BACKGROUND: Bipolar depression accounts for most of the disease duration in type I and type II bipolar disorder (BD), with few treatment options, often poorly tolerated. Many individuals do not respond to first-line therapeutic options, resulting in treatment-resistant bipolar depression (B-TRD). Esketamine, the S-enantiomer of ketamine, has recently been approved for treatment-resistant...

Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: ASystematic Review of the Current Literature

Current Neuropharmacology October 20, 2022 Alessio Mosca, Stefania Chiappini, Andrea Miuli et al. 30 citations

BACKGROUND: Ibogaine and noribogaine are psychedelic substances with dissociative properties naturally occurring in plants of the Apocynaceae family. Research has shown their efficacy in treating substance use disorders (SUD), particularly in opiate detoxification, but their efficacy and toxicity are still unclear. OBJECTIVE: This review aims to assess the anti-addictive role of ibogaine and...

Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study.

Drug and Alcohol Dependence October 1, 2021 Valerio Ricci, F. Ceci, Francesco di Carlo et al.

BACKGROUND Cannabis is the most used recreational drug worldwide. Its use can increase the risk of developing psychotic disorders and exacerbate their course. However, the relationship between cannabis use and dissociative symptoms has been scarcely investigated. AIMS To examine differences in psychotic and dissociative symptoms, and in functioning in first-episode psychotic patients (FEPp)...

Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

Brain Sciences June 27, 2021 Giovanni Martinotti, Stefania Chiappini, Mauro Pettorruso et al. 114 citations

The obsessive-compulsive spectrum refers to disorders drawn from several diagnostic categories that share core features related to obsessive-compulsive disorder (OCD), such as obsessive thoughts, compulsive behaviors and anxiety. Disorders that include these features can be grouped according to the focus of the symptoms, e.g., bodily preoccupation (i.e., eating disorders, ED) or impulse control...

New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review.

Experimental Neurology May 1, 2021 Fabrizio Schifano, Stefania Chiappini, Andrea Miuli et al. 49 citations

The use of several new psychoactive substances (NPS) has become very popular and is posing global health risks. Chemically and pharmacologically diverse molecules are constantly emerging and are presenting with a wide range of clinical implications. Serotonin toxicity, and specifically Serotonin Syndrome (SS), might develop as a result of an over-activation of the serotoninergic system caused...

The Benzydamine Experience: A Systematic Review of Benzydamine Abuse

Current Neuropharmacology January 14, 2021 Stefania Chiappini, Andrea Miuli, Alessio Mosca et al. 19 citations

BACKGROUND: Both prescription and over-the-counter (OTC) drugs recently emerged among novel psychoactive substances (NPS) being reported as ingested for recreational purposes. Among them, benzydamine (BZY), normally prescribed as an OTC anti-inflammatory drug, is reportedly being diverted and recreationally used. OBJECTIVE: The aim of this study was to investigate how the misuse of BZY has been...

Club Drugs: Psychotropic Effects and Psychopathological Characteristics of a Sample of Inpatients

Frontiers in Psychiatry August 31, 2020 Giovanni Martinotti, Attilio Negri, Stefania Schiavone et al. 22 citations

In this study, we described the acute psychiatric presentations related to recreational drug use in subjects on holiday in Ibiza. The use of psychoactive substances was characterized by poly-use of both traditional and novel substances, with several psychopathological consequences. Future research should focus on a better understanding of the psychopathological effects of specific substances,...

Substance-related exogenous psychosis: a postmodern syndrome

CNS Spectrums June 25, 2020 Giovanni Martinotti, Luisa de Risio, Chiara Vannini et al. 102 citations

There is growing recognition that substance use is associated with the emergence of psychosis.Elements of post-modernity dominate contemporary social contexts and operate as existential background factors that contribute to the emergence of substance-related psychotic phenomena, particularly use of potent and highly rewarding novel psychoactive substances (NPS). About 25% of first-episode...

An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine

Current Topics in Medicinal Chemistry January 31, 2020 Domenico de Berardis, Carmine Tomasetti, Maurizio Pompili et al. 38 citations

BACKGROUND: A research on mood disorder pathophysiology has hypothesized abnormalities in glutamatergic neurotransmission, by suggesting further investigation on glutamatergic N-methyl-Daspartate (NMDA) receptor modulators in treating Major Depressive Disorder (MDD). Esketamine (ESK), an NMDA receptor antagonist able to modulate glutamatergic neurotransmission has been recently developed as an...

Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study

Journal of Psychoactive Drugs February 9, 2019 Lorenzo Moccia, A. Tofani, Marianna Mazza et al. 10 citations

Novel psychoactive substances (NPSs) have currently become a major public health concern because of relatively easy accessibility to these compounds and difficulty in identifying them with routine laboratory techniques. Here, we report the 18F-fluorodeoxyglucose positron emission tomography/computerized tomography (18F-FDG PET/CT) case study of a 23-year-old man who developed a...

Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors

International Journal of Molecular Sciences September 23, 2018 Domenico de Berardis, Michele Fornaro, Alessandro Valchera et al. 171 citations

Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is...

Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives

Brain Sciences March 16, 2018 Giovanni Martinotti, Rita Santacroce, Mauro Pettorruso et al. 171 citations

Hallucinogen Persisting Perception Disorder (HPPD) is a rare, and therefore, poorly understood condition linked to hallucinogenic drugs consumption. The prevalence of this disorder is low; the condition is more often diagnosed in individuals with a history of previous psychological issues or substance misuse, but it can arise in anyone, even after a single exposure to triggering drugs. The aims...

Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset

CNS & Neurological Disorders - Drug Targets April 17, 2017 Giovanni Martinotti, Rita Santacroce, Duccio Papanti et al. 62 citations

BACKGROUND: Synthetic Cannabinoids (SC) are the widest and most diffused class of Novel Psychoactive Substances. The short- and long- term health risks associated with the consumption of SC are often unknown to both users and health professionals. This review aims to provide a synthesis of the most recent and relevant insights on the pharmacology, clinical and psychopathological aspects of SC....

25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug

BioMed Research International 2014 Francesco Saverio Bersani, Ornella Corazza, Gabriella Albano et al. 98 citations

Introduction. The use of novel psychoactive substances (NPSs) has rapidly increased as well as their online availability. The aim of this paper is to provide a comprehensive review of the nature and the risks associated with 25C-NBOMe, which has recently appeared in the drug market. Methods. A systematic analysis of the scientific literature and a qualitative assessment of online and media...

The dimensional assessment of personality in pathologic and social gamblers: the role of novelty seeking and self-transcendence

Comprehensive Psychiatry April 20, 2006 Giovanni Martinotti, Sara Andreoli, Emanuela Giametta et al. 67 citations

ObjectiveA few personality traits are characteristic of pathologic gamblers (PGs), but it is not clear if and how their personality profile differs from that of non-pathologic gamblers (non-PGs).MethodsSixty-five non-clinical subjects, differentiated into non-PGs and PGs with the means of the South Oak Gambling Screen (SOGS) and Diagnostic and Statistical Manual of Mental Disorders-Fourth...

New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic').

Journal of psychopharmacology (Oxford, England) November 1, 2005 Fabrizio Schifano, Paolo Deluca, Lisa Agosti et al. 70 citations

2C-T-7 ('Blue Mystic'), an illicit compound which shows similarities with MDMA and other designer drugs, has been only occasionally identified in the EU, but discussion on the Internet between experimenters has recently grown significantly. We aimed at collecting together in a review the available information on 2C-T-7, both at the cyber and at the street market level. 2C-T-7 was first...